The role of Qishen Yiqi dripping pills in treating chronic heart failure: An overview of systematic reviews and meta-analyses

Chen, Wensheng; Chen, Jiezhen; Wang, Yuanping; Yan, Jiaqi; Yan, Xin; Wang, Dawei; Liu, Yuntao

doi:10.3389/fcvm.2022.1001072

Cited by 3 publications

(4 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings of the poor methodological quality of SRs in the food field are in line with those from assessments of the methodological quality of SRs that used the AMSTAR 2 tool in other fields, including acupuncture [16,17], dentistry [18], Tai Chi [19,20], surgery [21,22], major depression in adults [23], chronic obstructive pulmonary disease [24], cardiovascular risk [25], physical activity [26], pancreatic cancer [27], chronic heart failure [28], cancerrelated fatigue [29], Alzheimer's disease [30], chronic spinal pain [31], neonatal pain [32], hip fractures [33], and atopic eczema [34]. Although the target patients or participants and interventions in those studies differed between each study, all demonstrated that the majority of SRs included had low methodological quality ("low" or "critically low").…”

Section: Findings In Contextsupporting

confidence: 82%

See 1 more Smart Citation

A Cross-Sectional Study Based on Forty Systematic Reviews of Foods with Function Claims (FFC) in Japan: Quality Assessment Using AMSTAR 2

Kamioka

Origasa

Tsutani³

et al. 2023

Nutrients

View full text Add to dashboard Cite

Background: The Foods with Function Claims (FFC) was introduced in Japan in April 2015 to make more products available that are labeled with health functions. The products’ functionality of function claims must be explained by scientific evidence presented in systematic reviews (SRs), but the quality of recent SRs is unclear. This study assessed the quality of SRs in the FFC registered on the Consumer Affairs Agency (CAA) website in Japan. Methods: We searched the database from 1 April to 31 October 2022. Confidence in the methodological quality of each SR was evaluated by the AMSTAR 2 checklist. Results: Forty SRs were randomly extracted on the basis of the eligibility criteria and recruitment procedures. Overall confidence was rated as “high” (N = 0, 0%), “moderate” (N = 0, 0%), “low” (N = 2, 5%), or “critically low” (N = 38, 95%). The mean AMSTAR 2 score was 51.1% (SD 12.1%; range 19–73%). Among the 40 SRs, the number of critical domain deficiencies was 4 in 7.5% of SRs, 3 in 52.5% of SRs, 2 in 35% of SRs, and 1 in 5% of SRs. Registering the review’s protocol and comprehensive search strategies were particularly common deficiencies. Additionally, the risk of bias (RoB) was insufficiently considered. Conclusion: Overall, the methodological quality of the SRs based on the FFC, introduced eight years earlier, was very poor. This was especially true in the interpretation and discussion of critical domains, which had many deficiencies in terms of protocol registration, a comprehensive literature search strategy, and accounting for the RoB.

show abstract

Section: Findings In Contextsupporting

confidence: 82%

“…A lack of protocol registration was the most problematic issue with the articles included in this study, and this was quite common in previous studies in other research fields [18,[23][24][25]28,30,34]. PROSPERO [36] is a well-known register of SRs, and future SR implementers must be registered.…”

Section: Findings In Contextmentioning

confidence: 99%

A Cross-Sectional Study Based on Forty Systematic Reviews of Foods with Function Claims (FFC) in Japan: Quality Assessment Using AMSTAR 2

Kamioka

Origasa

Tsutani³

et al. 2023

Nutrients

View full text Add to dashboard Cite

show abstract

“…As a traditional Chinese medicine compound preparation, QSYQ has been widely used in China in the combined treatment of HF patients, owing to its efficacy of “benefiting qi and activating blood circulation”, and has achieved good therapeutic effects. A newly published reappraisal analysis of systematic reviews on QSYQ ( 82 ) points out the current lack of attention to the impact of QSYQ on mortality and readmission rates in patients with HF, even in one of the largest systematic evaluations incorporating 85 studies ( 11 ). With the popularization of the concept of heart failure vulnerable period ( 83 ) and the emphasis on the prognosis of patients with HF, more and more relevant studies have been published.…”

Section: Discussionmentioning

confidence: 99%

Clinical efficacy and safety of adjunctive treatment of chronic ischemic heart failure with Qishen Yiqi dropping pills: a systematic review and meta-analysis

Xingmeng,

Guohua,

Hui

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

ObjectivesOur study was to evaluate the effect of Qishen Yiqi Dropping Pills(QSYQ) on the prognosis of chronic ischemic heart failure(CIHF) and its safety.MethodsDatabases including CNKI, Wanfang, VIP, CBM, PubMed, Web of Science, The Cochrane Library and EMbase were searched from their inception to April 2023 to screen relevant randomized controlled trials (RCTs). Primary indicators included readmission rates, rates of major adverse cardiovascular events (MACE), and all-cause mortality rates. The quality of the literature was assessed according to the Cochrane Reviewers' Handbook 5.0 and the Modified Jadad Scale (with a score of 4–7 rated as high quality). Meta-analysis was performed using the meta-package created by R software version 4.2.3, continuous data were compared using SMDs, and dichotomous and ordered data were compared using ORs; and the I2 test was used to assess the heterogeneity.ResultsFifty-nine studies out of 1,745 publications were finally included, totalling 6,248 patients. Most studies were poorly designed and had some publication bias, with only 26 high-quality papers (Jadad score ≥4). Meta-analysis showed that the combined application of QSYQ was able to reduce the readmission rate [OR = 0.42, 95% CI (0.33, 0.53), P < 0.001], all-cause mortality rate [OR = 0.43, 95% CI (0.27, 0.68), P < 0.001], and the incidence of MACE [OR = 0.42, 95% CI (0.31, 0.56), P < 0.001]. Also, the treatment method can improve clinical effectiveness [OR = 2.25, 95% CI (1.97, 2.58), P < 0.001], increase 6-min walking distance (6MWD) [SMD = 1.87, 95% CI (1.33, 2.41), P < 0.0001] and left ventricular ejection fraction (LVEF) [SMD = 1.08, 95% CI (0.83, 1.33), P < 0.0001], and decrease the Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores [SMD = −2.03, 95% CI (−3.0, −1.07), P < 0.0001], BNP levels [SMD = −2.07, 95% CI (−2.81, −1.33), P < 0.0001] and NT-ProBNP levels [SMD = −2.77, 95% CI (−4.90, −0.63), P < 0.05]. A total of 21 studies (n = 2,742) evaluated their adverse effects, of which 13 studies reported no adverse effects and 8 studies reported minor adverse effects.ConclusionOur results suggest that the combined application of QSYQ can further improve patients' cardiac function and exercise tolerance, improve their quality of life, and ultimately improve patients' prognosis with a favorable safety profile. Nonetheless, limited by the quality and high heterogeneity of the literature, we must be conservative and cautious about the present results.Systematic Review RegistrationPROSPERO (CRD42023449251).

show abstract

“…Clinically, Zhang et al (2022) proved that it mainly treats symptoms of qi deficiency and blood stasis, such as chest tightness and chest pain, shortness of breath, and spontaneous sweating. Chen L, et al (2022) found that Qishen Yiqi dripping pills mainly play an auxiliary role in the treatment of patients with coronary heart disease, and Chen W, et al (2022) demonstrated that Qishen Yiqi dripping pills could be combined with Western medicine to treat diseases such as hypertension and angina.…”

Section: Introductionmentioning

confidence: 99%

Determination of Four Chemical Components in Qishen Yiqi Dripping Pills by UPLC-MS/MS Method

Lili,

Honglian,

Yanxia

et al. 2023

Pharmacognosy Magazine

View full text Add to dashboard Cite

Background In this study, the ultrahigh performance liquid chromatography mass spectrometry/mass spectrometry (UPLC-MS/MS) method was established to test the contents of protocatechuic acid (C7H6O4), salvianolic acid B (C36H30O16), rosmarinic acid (C19H14O3), and cryptotanshinone (C19H20O3) in Qishen Yiqi dripping pills. Materials and Methods Methanol was chosen as the solvent according to a certain material–liquid ratio as a solution, and the ultrasonic extraction method was used to prepare the sample solution. UPLC-MS/MS was used to complete a quantitative analysis of the contents of Qishen Yiqi dripping pills. Then, the chromatographic conditions were shown as follows. The stationary phase was Agilent ZORBAX SB-C18 (2.1 mm × 100 mm, 1.8 µm), and the mobile phase was acetonitrile–0.1% formic acid water. The column temperature was 40℃, the injection volume was 3 µL, and the flow rate was 0.2 mL⋅min–1. Finally, the determination method was built to test four chemical constituents under the multiple reaction monitoring (MRM) analysis mode. Results The retention times of protocatechuic acid, salvianolic acid B, rosmarinic acid, and cryptotanshinone were 1.26, 1.32, 1.35, and 6.76 min, respectively. In addition, the concentration ranges of four compounds were 0.25–2.0 µg⋅mL–1, 10.0–50.0 µg⋅mL–1, 5.0–50.0 µg⋅mL–1, and 1.0–10.0 µg⋅mL–1, respectively. And the standard curve showed a good linear relationship in a reasonable range ( r2 ≥ 0.9950). The average recovery rate was from 96% to 124%. The contents of protocatechuic acid, salvianolic acid B, rosmarinic acid, and cryptotanshinone were 0.12%–0.022%, 17%–8.4%, and 6.5%–8.6% in seven batches of Qishen Yiqi dripping pills, which were in the range of 23%–31%. The instrument ran stably, and the method had good accuracy and repeatability (relative standard deviation [RSD] ≤ 3%). Additionally, the test result was stable within 10 h. Conclusion The contents of the four constituents were different among different batches. The quantitative method was established to determine the four chemical components in Qishen Yiqi dripping pills, which could provide a reference for quality evaluation in vivo.

show abstract

The role of Qishen Yiqi dripping pills in treating chronic heart failure: An overview of systematic reviews and meta-analyses

Cited by 3 publications

References 47 publications

A Cross-Sectional Study Based on Forty Systematic Reviews of Foods with Function Claims (FFC) in Japan: Quality Assessment Using AMSTAR 2

A Cross-Sectional Study Based on Forty Systematic Reviews of Foods with Function Claims (FFC) in Japan: Quality Assessment Using AMSTAR 2

Clinical efficacy and safety of adjunctive treatment of chronic ischemic heart failure with Qishen Yiqi dropping pills: a systematic review and meta-analysis

Determination of Four Chemical Components in Qishen Yiqi Dripping Pills by UPLC-MS/MS Method

Contact Info

Product

Resources

About